Drug developer CoGenesys said that David U’Prichard has been appointed to the company’s board of directors.
U’Prichard currently sits on the boards of Invitrogen and SR Pharma, the parent firm of Atugen.
Note to Readers: This is the last issue of RNAi News to publish in 2006. The next issue of the newsletter will appear on Thursday, Jan. 4. |